Michael J. Mauro, MD, provides a summary of the SIMPLICITY trial. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
Author: Editor
Stuart L. Goldberg, MD provides CML meeting highlights live from the 2015 ASCO Annual Meeting that significantly impact practice. For additional meeting highlights from other congresses, http://managingcml.com/con-ed-cml/annual-meeting-highlights-cml For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
Dr. Karen Seiter discusses the efficacy and safety considerations in using ponatinib. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
Dr. Karen Seiter discusses the most common reasons for treatment failur For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
Dr. Karen Seiter discusses using second-generation TKIs as a first-line approach. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
Dr. Karen Seiter explains how to recognize treatment failure or treatment resistance in CML patients. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results of a phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lenvatinib is an oral tyrosine kinase inhibitor of the VEGFR13, FGFR14, PDGFR?, RET, and KIT signaling networks. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary results of the multi-arm phase 1 TATTON trial, which evaluated the mutant-selective EGFR tyrosine kinase inhibitor, AZD9291, combined with MEDI4736 (anti-PD-L1 monoclonal antibody), savolitinib (MET inhibitor) or selumetinib (MEK1/2 inhibitor) in patients with EGFR-mutant lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Is there a role for second-line therapy in advanced pancreatic cancer? For more information, tools, resources and CE activities please http://partnersinpancreaticcancer.com/ Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.
Dr. Koushik Das discusses the type of patients that would benefit from pancreatic cancer screening. For more information, tools, resources and CE activities please http://partnersinpancreaticcancer.com/ Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.
Dr. Koushik Das discusses screening tests and predictive biomarkers for pancreatic cancer. For more information, tools, resources and CE activities please http://partnersinpancreaticcancer.com/ Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.
Dr. Jill Lacy discusses radiotherapy in the treatment of pancreatic cancer, how its role is evolving in specific settings, and when and how to use radiotherapy in pancreatic cancer. For more information, tools, resources and CE activities please partnersinpancreaticcancer.com Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.
Dr. Jill Lacy discusses the development of immune therapies for pancreas cancer, the progress that is being made, and provides an update on CRS-207 and GVAX.
At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, provides an update on the safety results of the phase 3 SABRINA study, which is comparing subcutaneous and intravenous rituximab in the maintenance setting of patients with follicular lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Marek Trn?ný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the results of the subgroup analysis of the phase 2 multicentre, randomised, open-label MCL-002 (SPRINT) trial of lenalidomide, an immunomodulator with antineoplastic and antiproliferative effects, versus investigators choice (chlorambucil, cytarabine, fludarabine, gemcitabine, or rituximab) in patients with relapsed/refractory mantle cell lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses ongoing clinical studies by the German CLL Study Group (GCLLSG) that are investigating new therapies for patients with chronic lymphocytic leukaemia (CLL), including obinutuzumab in combination with chlorambucil; a watch-and-wait strategy; and a four-arm study comparing standard chemotherapy versus non-chemotherapy-containing regimens. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the first results from the phase 3 HELIOS trial, which evaluated the first-in-class, oral covalent Bruton’s tyrosine kinase inhibitor, ibrutinib, in combination with bendamustine and rituximab (BR) versus BR plus placebo in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the ClÃnica Universidad de Navarra, Navarra, Spain, discusses the results of the multicentre, open-label, randomised phase 3 ENDEAVOR study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the results of the Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) study. EXELS study is an observational phase 4 study that compared safety, pregnancy outcomes, and efficacy (measured by incidence of thrombohaemorrhagic events and platelet reduction) of anagrelide compared with other cytoreductive therapies in high-risk patients with essential thrombocythemia (ET). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Breast Cancer Index (BCI) is a molecular, gene expression-based test uniquely positioned to identify patients best suited for extended endocrine treatment. It is the only validated, commercially available test that provides prognostic risk of late recurrence (5-10 years post-diagnosis), as well as prediction of extended endocrine therapy benefit. The breakthrough test helps oncologists and patients navigate the difficult trade-off between wanting to take steps to prevent recurrence of their disease and facing significant side effects and safety challenges related to extended endocrine therapy. Breast Cancer Index (BCI) was granted Medicare coverage in October 2014. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com…
Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies. For more information, visit: http://www.cancertypeid.com
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses the trial design and results of the phase 3 PERSIST-1 trial of pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses follow-up data of the RESPONSE trial, which is a multicentre, open-label phase 3 study evaluating the efficacy and safety of ruxolitinib compared with best available therapy in patients with polycythemia vera resistant to or intolerant of hydroxyurea. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, MarÃa-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the results of the phase 2 MMY2002 trial of the anti-CD38 monoclonal antibody, daratumumab, in patients with at least 3 lines of prior therapy or double refractory multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomised, open-label phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma. Daratumumab is a novel therapeutic human CD38 monoclonal antibody. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses the results of the phase 3 PERSIST-1 trial of the selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3, pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Patrick I. Borgen, M.D, of the Brooklyn Breast Cancer Center talks about reducing opioids in breast cancer surgery using Bupivacaine
Charles L. Loprinzi, MD, of the Mayo Clinic discusses the management of Hot Flashes using SSRI, Gabapentin, Venlafaxine in patients with breast cancer
Charles L. Loprinzi, MD, of the Mayo Clinic reviews how Olanzapine Decreases Nausea and Vomiting in Patients With Esophageal, Head and Neck Cancer
Charles L. Loprinzi, MD, of the Mayo Clinic talks about scrambler therapy for the treatment of chemotherapy- induced peripheral neuropathy
Hope S. Rugo, MD of the UCSF Medical Center talks about the I-SPY 2 Trial and MK-2206 which shows benefit for breast cancer patients
Hope S. Rugo, MD of the UCSF Medical Center discusses numerous trials associated with checkpoint inhibitors in triple negative breast cancer
Hope S. Rugo, MD of the UCSF Medical Center discusses the state of CDK 4/6 Inhibitors for Patients with HR+/HER- Breast Cancer
Hope S. Rugo, MD of the UCSF Medical Center discusses scalp cooling system which prevented significant hair loss in 70.3% of patients with breast cancer receiving adjuvant CTX
Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that DNMT3A R882 mutations were associated with an increased risk of minimal residue disease (MRD) at the time of complete remission. DNMT3A R882 mutations may therefore be important in chemoresistance in AML. A novel genetic mouse model was used to study the role of DNMT3A R882 mutations in AML pathogenesis and chemoresistance. Presented by Olga Guryanova, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, at the 20th Congress of the European Hematology Association (EHA) European Medical Journal Website: http://emjreviews.com/…
Maha Hussain, MD of University of Michigan Comprehensive Cancer Center discusses Phase II Androgen Deprivation Therapy with Palbociclib
Maha Hussain, MD of the University of Michigan Comprehensive Cancer Center discusses ETS Gene Fusions as a Predictive Biomarker in Prostate Cancer
Robert J. Mayer, MD of Dana-Farber Cancer Institute discusses the results of the TAS-102 Trial for Refractory Metastatic Colorectal Cancer
HOWARD A. “SKIP” BURRIS, III, MD of Sarah Canon discusses the PD-1 Benefit in Progression Free Survival for Non-Small Cell Lung Cancer
Nicholas J. Vogelzang, MD or the University of Illinois discusses the expanded access of Radium-223 for prostate cancer patients
Nicholas J. Vogelzang, MD of the University of Illinois discusses second line bladder cancer and PD-L1 antibody
Nicholas J. Vogelzang, MD of the University of Illinois discusses a new trial Sunitinib v. PD-L1 with Bevacizumab
Nicholas J. Vogelzang, MD of the University of Illinois discusses the state of kidney cancer June 2015
Jason Luke, MD of the University of Chicago discusses Phase III Trial Pembrolizumab is Better Than Ipilimumab for Advanced Melanoma
Jason Luke, MD of the University of Chicago discusses gene expression profiling and immune signatures
Jason Luke, MD, of the University of Chicago discusses the Ipilimumab and Nivolumab Combination Study
The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free survival and relapse-free survival in younger patients with acute myeloid leukaemia (AML). Presented by Gerhard Ehninger, MD, Technical University Dresden, Dresden, Germany, at the 20th Congress of the European Hematology Association (EHA) European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result in the identification of therapeutic targets for these bleeding disorders. Half of the patients had thrombocytopaenia. Several patients showed similar platelet abnormalities as the earlier reported patients with the GFI1B defect, such as decreased ?-granule numbers and/or platelet CD34 expression. The GFI1B protein is known to regulate gene expression. Almost all GFI1B variants were still active, while one had lost this function in transcription repression assays. If the new GFI1B variants are disease-causing, this would indicate a distinct molecular mechanism…
The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with myelofibrosis. Patient-reported outcomes (PROs), which have become important for approval of new therapies, was also measured to determine whether pacritinib reduced patients symptom burden and helped them feel better. Presented by Ruben Mesa, MD, FACP, Mayo Clinic, Scottsdale, AZ, at the 20th Congress of the European Hematology Association (EHA) European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews